Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other Operating Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other Operating Expenses for 15 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.5 million through Dec 2025, up 9.71% year-over-year, with the annual reading at $2.1 million for FY2023, N/A changed from the prior year.
  • Other Operating Expenses hit $17.3 million in Q4 2025 for Ligand Pharmaceuticals, up from $11.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $37.7 million in Q2 2024 to a low of -$37.6 million in Q4 2021.
  • Historically, Other Operating Expenses has averaged $11.2 million across 5 years, with a median of $12.3 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: tumbled 6166.67% in 2021 and later soared 268.87% in 2024.
  • Year by year, Other Operating Expenses stood at -$37.6 million in 2021, then skyrocketed by 135.32% to $13.3 million in 2022, then plummeted by 84.03% to $2.1 million in 2023, then surged by 1675.29% to $37.7 million in 2024, then tumbled by 54.1% to $17.3 million in 2025.
  • Business Quant data shows Other Operating Expenses for LGNDZ at $17.3 million in Q4 2025, $11.1 million in Q3 2025, and $12.4 million in Q2 2025.